Shawn Levy, Ph.D., received his graduate and postdoctoral training from Emory University. Before joining HudsonAlpha in 2009, Levy served as faculty at Vanderbilt University Medical Center and was the founding director of the Vanderbilt Microarray Shared Resource. Levy currently directs the Genomic Services Laboratory supporting projects that utilize genomic technologies from laboratories around the world. Since 2009, the Genomics Services Laboratory has supported more than 800 projects and contributed to dozens of manuscripts and grants.
Current research areas include:
• Technology Development and Optimization. Recent and major areas of interest have been the development of highly efficient molecular barcodes for multiplexing multiple samples per sequencing lane on the Illumina sequencing platform. The lab has developed a multiplexing method that is not only efficient and easy to use, but it is able to support multiplexing of over 700,000 samples per sequencing lane. HudsonAlpha is in the process of filing a patent disclosure for this method.
• De novo mutation detection and the role of these mutations in neurological disease including Autism and Schizophrenia. Aside from the DNA sequences inherited from our parents, every person has a small number of unique genetic changes that are referred to as de novo mutations. These mutations have recently begun to be associated with a growing number of complex diseases.
• The molecular responses of the immune system and microbiome to vaccines, organ transplant procedures and chemotherapy. We are leveraging the resolution of current genomic technologies to provide an unprecedented view of the molecular responses of the immune system to common vaccines like the annual flu vaccine as well as investigating how technology can improve transplant survival and predict severe side effects to intensive therapies such as chemotherapy for cancer treatment.
Selected recent publications
Xu, B., et al. (2011). Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nature Genetics. 43: 864-868.
Rademakers R, et al. (2011). Mutations in the colony stimulating factor 1 receptor (CSF1R) cause hereditary diffuse leukoencephalopathy with spheroids. Nature Genetics. 44(2), 200-205.
Powell AE, et al. (2012). Lrig1, a pan-ErbB negative regulator, marks intestinal stem cells and acts as a tumor suppressor. Cell. 149(1), 146-158.
Fiskerstrand T, et al. (2012). Familial Diarrhea Syndrome Caused by an Activating GUCY2C Mutation. New England Journal of Medicine. 366(17), 1586-1595.
Neale, B. M., et al. (2012). Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 485: 242-245.
Chaki M, et al. (2012). Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell. 2012. 150(3), 533-548.
Zhou W, et al. (2012). Nature Genetics. 2012. 44(8), 910-915.
Xu B, et al. (2012). De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nature Genetics. In press.